Beyond their metabolic effects, GLP-1 RAs have demonstrated cardiovascular and renal benefits in large outcome trials, including reductions in major adverse cardiovascular events (MACE) and attenuation of albuminuria progression ( Table 1 , renal eligibility criteria across landmark GLP-1 RA cardiovascular and kidney outcome trials consistently excluded dialysis-dependent patients, resulting in a persistent lack of randomized evidence in this high-risk population
doi: 10.1007/S10067-021-06001-1 111 McMahonDEGallmanAEHruzaGJRosenbachMLipoffJDesaiSRet al
Research shows that GLP-1 users should aim for roughly 1.2 grams of protein per kilogram of body weight per day to preserve lean muscle mass while the scale goes down
Strengths: No needles Higher bioavailability than oral spray for some peptide sequences Convenient, discreet administration Does not require first-pass metabolism considerations Considerations: Patient technique still matters Nasal irritation in some patients Seasonal nasal congestion can affect absorption Sublingual: A Close Cousin to Oral Spray Sublingual delivery places the peptide under the tongue for mucosal absorption
In particular, GSTP1-1 is able to protect the tumor cells from apoptosis signals by inhibiting c-Jun N-terminal kinase (JNK)a member of the MAPK pathwaynon-catalytically, by direct proteinprotein association 25,26
GLP-1 microdosing refers to the use of very low doses of prescription GLP-1 medications